

Updated on: 14th October 2024

CERTIFICATE OF ANALYSIS

Lot#: CHF2313-HE-Z

PRODUCT DESCRIPTION

Reference: HuHECS/4Product: Cryopreserved Human Hepatocytes
Category: Suspension

Isolation date: 26th October 2023
Initial Isolation Viability: 72.40%
Storage conditions: -196°C using LN₂

Spheroid qualified: No Sterility test: negative for mycoplasma, bacteria,


Organoid qualified: Yes yeast, and fungi

DONOR DEMOGRAPHICS

Species	Gender	Race	Age	вмі	Smoker	Alcohol Use	Drug Use	
Human	Female	Caucasian	69	27.27	>20	Yes	No	
Pathology			Serological Data ¹					
Metastatic tumor				Tested negative less than 3 months before surgery				

Patient informed consent was obtained. ¹The donor was serologically tested negative for following infectious diseases: HIV, Hepatitis B and C, and SARS-CoV-2. Donor medical history was also examined prior to accepting this donor. *For donor's medication information, please contact us.*

DONOR HISTOLOGY



- Hematoxylin & Eosin: Parenchyma with normal appearance and with no signs of steatosis or fibrosis present.
- Sirius red: The liver has no signs of fibrosis, with only a very discrete accumulation of Sirius red staining in portal areas. Minimal matrix deposition in the sinusoidal areas.
- Oil red: No areas of steatosis with red oil staining accumulation were detected.

Conclusions: Liver in normal condition with no apparent steatosis or fibrosis.

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.




CHARACTERIZATION FOR SUSPENSION CELLS

Post Thaw Lot information	Result	SD	n
Number of viable cells (cells/vial):	4.64x10 ⁶	± 1.12x10 ⁶	9
Post-thaw viability (%):	81.12	± 4.34	9

Human hepatocytes were thawed according to BeCytes Biotechnologies protocol. The post-thawing yield and viability (trypan blue exclusion assay) of hepatocytes were assessed after a purification process.

Time (h)	0	0.5	1	1.5	2	3	4	5
Viability (%)	81.12	78.70	73.15	76.85	72.82	71.78	78.07	72.66
SD	± 0.00	± 0.86	± 0.57	± 3.46	± 2.18	± 6.48	± 2.36	± 0.51



Resuspended human hepatocytes suspension ($0.5 * 10^6$ cells in 0.5 ml medium) from the post-thaw assessment were incubated up to 5 h at 37°C. The assay was performed in 2 ml round-bottom tubes under shaking conditions (1000 rpm) using Eppendorf Thermomixer C. In the first two hours, samples were taken at every 30 min, after 2 h samples were taken at every 60 min. At each time point the viability of cells was calculated.

3D HEPATIC SPHEROID AND ORGANOID FORMATION

Spheroid morphology	Organoid morphology
This lot is not suitable for 3D spheroid culture according to BeCytes Technologies protocols	

Primary hepatocytes were validated for their capacity to generate liver organoids. After thawing the cells using BeCytes Technologies' thawing protocols and media, 150.000 hepatocytes were mixed with 50 μ l of Matrigel® and cultured using the procedure described by Huch et al. (2014). For more information/protocols about 3D hepatic organoids, contact us.

If you need help for an experiment, just contact us, our experts will be pleased to assist you

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.



CERTIFICATION:

The viability and performance of the primary human hepatocytes provided depend primarily on the use of appropriate media and reagents, as well as the use of sterile plastics. Likewise, proper handling protocols must be followed. Please note that if these parameters are not carefully considered, the cellular response obtained in the assays may be lower than expected.

Name	Tittle	Signature	Cytes Biotechnologies, S.L.	Date
Pilar Sainz de la Maza	Quality Manager	Flor fair lend	CYTES BIOTECHHOLOGIES S.L.	14/10/24

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.